Gilead Sciences: Virus Diseases trials
The registry lists 19 Virus Diseases studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 1 4Phase 2 7Phase 3 3No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated CirrhosisCompletedNCT02996682Phase 3Results posted
- Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing RegimenCompletedNCT02822794Phase 3Results posted
- Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver TransplantCompletedNCT02781571Phase 2Results posted
- Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus InfectionCompletedNCT02722837Phase 3Results posted
- Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) InfectionCompletedNCT02534350Phase 2Results posted
- Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation SettingCompletedNCT02350569Phase 2Results posted
- Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02185794Phase 1Results posted
- Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical PracticeCompletedNCT02783976
- Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in IndiaCompletedNCT02592057
- Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus InfectionCompletedNCT02562742
- Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus InfectionCompletedNCT02537379
- Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of AgeCompletedNCT01754428
- A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus InfectionCompletedNCT01590654Phase 1
- Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT01431898Phase 1
- GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC GenotypeTerminatedNCT01384383Phase 2
- Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus InfectionCompletedNCT01371578Phase 2
- A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT01316237Phase 1
- Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus InfectionCompletedNCT01072695Phase 2
- Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus InfectionTerminatedNCT00874796Phase 2